Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2022-08-30 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2022-08-30 English
Interim MD&A - English.pdf
Regulatory Filings
2022-08-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-08-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of Theralase Technologies Inc.'s intellectual property portfolio, specifically the granting of a Brazilian patent related to their Anti-Cancer Technology platform. It discusses the company's clinical study progress, patent details, and forward-looking statements about future commercialization and research plans. There are no financial statements, regulatory certifications, voting results, or detailed management reports. The content focuses on an update about intellectual property and company progress rather than a formal financial or regulatory filing. This type of announcement fits best under the category of a general regulatory announcement or compliance update that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-06-28 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Theralase Technologies' research paper has become one of the top 10 most downloaded papers in a scientific journal. It discusses the research, clinical studies (Phase Ib and Phase II), and forward-looking statements about the company's drug development progress. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, and no capital or financing updates. The document is primarily an announcement of research achievements and clinical study progress, not a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement related to research and development progress and clinical study updates. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other categories.
2022-06-24 English
News release - English.pdf
Regulatory Filings
2022-06-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.